Login
Navigate Fool.com
Will PRXL beat
the market?
Community Rating: 4 Stars: Favorite

50.15 0.19 (0.38%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.80
Previous Close $49.96
Daily Range $49.21 - $50.63
52-Week Range $37.53 - $57.25
Market Cap $2.8B
P/E Ratio 25.59
Dividend (Yield) $0.00 (0.0%)
Volume 411,113
Average Daily Volume 465,839
Current FY EPS $2.05

How do you think PRXL
will perform against the market?

Top PRXL Bull/Bear Pitches

 

BobLangley (< 20)
Submitted October 21, 2008

Considerable backlog exists for the services of this clinical research and marketing company whose stock has taken an unjustified hit of late.

0 Replies Reply Report this Post
 

PennyStockFool (< 20)
Submitted January 27, 2009

Taking today's (1/27) 30% gain on this stock and going Thumbs Down for a few weeks.

0 Replies Reply Report this Post

News & Commentary

4 Disruptive Stocks Biotechs Depend On

Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.

Thursday's ETF with Unusual Volume: IHF

First Week of May 17th Options Trading For PRXL

Drug Development Goes Global in 2014

Contract research organizations like Quintiles (Q), Parexel (PRXL), and Covance (CVD) are growing as big pharma pumps up pipelines to offset the patent cliff.

Organovo Holdings: The Best-Performing Biotechs of 2013

Here's why Organovo Holdings (NYSEMKT: ONVO) is up more than 200% this year.

Worried About Obamacare? Invest in This Sector Instead

Looking for health-care exposure in your portfolio, but want to steer clear of the Obamacare debate? Then this little-known health-care industry could be the answer.

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

2 Stocks to Watch: BP and PAREXEL

Here are two stocks our analysts will be watching closely this week. Will you be watching too?

Investor Beat, Nov. 19, 2013

The top business stories on JPMorgan, Home Depot and Best Buy for today's Foolish investor.

Why PAREXEL International Corp. Shares Sank

PAREXEL meets Wall Street's lofty profit expectations, but is derailed by its fifth quarterly decline in another key metric.

See More PRXL News...

Sector

Healthcare

Industry

Healthcare Information Services

PAREXEL International Corp (PRXL) Description

The Company provides a range of expertise in clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Website: http://www.parexel.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks